In what could be a monumental shift in diabetes care, a single infusion of a new cell-based treatment has allowed most patients in a small clinical trial to live insulin-free for the first time in years — or ever. Known as zimislecel, the therapy relies on stem cells transformed into insulin-producing islet cells, offering new hope for people with type 1 diabetes.
The therapy was developed by Vertex Pharmaceuticals and tested in a group of 12 individuals suffering from a particularly perilous form of type 1 diabetes: hypoglycemia unawareness. For these patients, blood sugar can plummet without warning, increasing the risk of fainting, seizures, or even death. After receiving the experimental treatment, 10 participants no longer required daily insulin shots, and the remaining two significantly reduced their need for the hormone.
“This is more than a milestone. It’s potentially life-altering,” said Dr. Mark Anderson, head of the diabetes center at the University of California, San Francisco, who was not involved in the study. “The idea of freeing people from insulin therapy is something we’ve been working toward for decades.”
The findings, unveiled at the American Diabetes Association’s annual meeting in Chicago and published in The New England Journal of Medicine, showcase the culmination of over 25 years of painstaking research. At the heart of the treatment is a relatively simple but powerful idea: use stem cells to replenish what the immune system has destroyed.
In type 1 diabetes, the immune system mistakenly attacks the pancreas’ islet cells — the very cells responsible for producing insulin. Zimislecel works by replacing them. The engineered islet cells are infused directly into the liver, where they take root and begin producing insulin naturally.
Patients in the study began seeing results fast. Within just three months, the terrifying drops in blood sugar stopped. By the six-month mark, most were off insulin entirely.
The inspiration behind this scientific leap dates back decades, when Harvard researcher Doug Melton set out to find a cure after both his children were diagnosed with type 1 diabetes. “I still can’t believe it worked,” Melton said. “We spent years failing before we found the right formula to turn stem cells into functioning islet cells.”
Eventually, Melton joined Vertex to help steer the therapy into clinical trials. Tragically, the first participant to receive the infusion, Brian Shelton, passed away not long after due to preexisting dementia. But his case proved the treatment could work.
Still, it’s not without complications. Patients must take immunosuppressive drugs to keep their body from rejecting the implanted cells — a lifelong tradeoff that can raise the risk of infection and possibly cancer. “It’s not the kind of immunosuppression we use for organ transplants, but the long-term safety is still uncertain,” noted Dr. Irl Hirsch, a diabetes specialist at the University of Washington.
Cost is another looming question. Vertex has not yet released a price, as the therapy is still awaiting FDA approval. But for patients living under the shadow of daily injections and sudden crashes in blood sugar, this therapy may offer something more valuable than any number: a chance to simply live.
One of those patients is Amanda Smith, a 36-year-old nurse from Canada. “Six months after the treatment, I was off insulin,” she said. “It’s like waking up in a different life.”
More trials are underway, and more time is needed. But the early results have rekindled hope in a field that’s long sought a breakthrough. If the promise of zimislecel holds, this could be the beginning of a new chapter for millions living with type 1 diabetes.
